Showing 3381-3390 of 4063 results for "".
- Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Diseasehttps://modernod.com/news/ocuphire-pharma-hosting-key-opinion-leader-event-on-oral-apx3330-for-diabetic-eye-disease/2481159/Ocuphire Pharma announced that it will host a key opinion leader (KOL) webinar highlighting oral APX3330, its lead drug candidate for diabetic retinopathy (DR) and diabetic macular edema (DME), on Friday, October 14, 2022 at 11 am to 12:30 pm Eastern Time. The event will
- Clearside: Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platformhttps://modernod.com/news/clearside-positive-data-presentations-at-aao-annual-meeting-demonstrate-utility-and-versatility-of-clearside-biomedicals-proprietary-suprachoroidal-space-platform/2481151/Clearside Biomedical announced that clinical data from multiple internal and partnered programs were presented at the recent 2022 Annual Meeting of the American Academy of Ophthalmology (AAO), the world's largest association of eye physicians and surgeons. “These data presenta
- Schwind Eye-Tech-Solutions Announces Management Changeshttps://modernod.com/news/schwind-eye-tech-solutions-announces-management-changes/2481149/Rolf Schwind, who was serving as CEO of Schwind eye-tech-solutions GmbH, has withdrawn from active leadership of the company, effective October 1, 2022, and joined the Advisory Board. In that capacity he will continue to contribute to the growth of Schwind with his more than 40 years of
- Shore Capital Partners Announces Sale of EyeSouth Partnershttps://modernod.com/news/shore-capital-partners-announces-sale-of-eyesouth-partners/2481146/Shore Capital Partners, a Chicago-based private equity firm, has announced the sale of EyeSouth Partners, an eye care management services organization, to Olympus Partners. Terms of the deal were not disclosed. Shore formed EyeSouth in 2017 with the goal of creating
- AAO: Latest Research From the World’s Largest Eye Disease Data Registryhttps://modernod.com/news/aao-latest-research-from-the-worlds-largest-eye-disease-data-registry/2481141/The IRIS Registry (Intelligent Research in Sight) powered several big data studies this year, most of which will be presented and discussed at AAO 2022, the 126th annual meeting of the American Academy of Ophthalmology. &n
- Visus Therapeutics Acquires Assets of ViewPoint Therapeuticshttps://modernod.com/news/visus-therapeutics-acquires-assets-of-viewpoint-therapeutics/2481124/Visus Therapeutics announced it has expanded its pipeline via the acquisition of all patents and other assets of ViewPoint Therapeutics. Financial terms of the deal were not disclosed. Founded in 2014, ViewPoint discovered and developed alpha-crystallin aggregation
- Bausch + Lomb Will Present Scientific Data and Analyses During World Cornea Congresshttps://modernod.com/news/bausch-lomb-will-present-scientific-data-and-analyses-during-world-cornea-congress/2481119/Bausch + Lomb announced the presentation of one podium and two poster presentations at the World Cornea Congress VIII meeting, which will take place in Chicago from September 28-29, 2022. 'The podium presentation will feature findings from the pivotal p
- Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIIIhttps://modernod.com/news/oyster-point-pharma-to-present-new-scientific-analyses-at-world-cornea-congress-viii/2481117/Oyster Point Pharma announced it will present new scientific analyses at World Cornea Congress VIII, which is taking place in Chicago from September 28-29, 2022. “We look forward to presenting our post-hoc analyses on the clini
- Cimerli, First Biosimilar Interchangeable to Lucentis, Set to Launch in the UShttps://modernod.com/news/coherus-to-launch-cimerli-ranibizumab-eqrn-in-the-us/2481103/Coherus BioSciences announced the commercial availability, beginning October 3, 2022, of Cimerli (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis (ranibizumab injection) for all approved indications. Cimerli was approved by the FDA in August 2022, having met FDA&rs
- Johnson & Johnson Vision Announces New Data and Sustainability Activities at ESCRShttps://modernod.com/news/johnson-johnson-vision-announces-new-data-and-sustainability-activities-at-escrs/2481095/Johnson & Johnson Vision will be presenting new data and participating in a series of events at the upcoming 40th European Society of Cataract and Refractive Surgeons (ESCRS) congress September 16-20, 2022. The congress, taking place at the Milano Convention Centre in Milan, Italy, will showc